# Artemisia absinthium L. ethanol extract inhibits the growth of gastrointestinal cancer cells by inducing apoptosis and mitochondria-dependent pathway

**Authors:** Ting Li, Shaoqi Yu, Zihang Ma, Jinyao Li, Lijie Xia, Yan Feng

PMC · DOI: 10.3389/fonc.2025.1644498 · Frontiers in Oncology · 2025-10-27

## TL;DR

Artemisia absinthium extract and its active ingredient Luteolinidin show anti-cancer effects on gastrointestinal cancers by inducing apoptosis and targeting key proteins.

## Contribution

The study identifies Luteolinidin as a key active compound and reveals its mechanism of action in gastrointestinal cancer treatment.

## Key findings

- AAEM-V showed strong in vitro and in vivo anticancer activity against gastrointestinal cancers.
- Luteolinidin targets SRC, EGFR, and AKT1 proteins and induces apoptosis via ROS production.
- The study provides insights into the molecular mechanisms of Artemisia absinthium in cancer treatment.

## Abstract

Artemisia absinthium L. has a long history in the treatment of gastrointestinal cancer (GIC), but its molecular mechanisms remain unclear.

We identified and validated the active components and key targets in A. absinthium for the treatment of GIC by LC-MS and Network analysis. The antitumor effect of A. absinthium ethanol extract (AAEM-V) against gastrointestinal tract cancer in vitro and in vivo as well as the anticancer activity of the active ingredient, Luteolinidin, were further evaluated.

AAEM-V exhibited good anticancer activity in vitro and in vivo. The active ingredient Luteolinidin was taken to intersect with the targets of gastric and colorectal cancers, and 69 common targets were identified. A total of three core targets, SRC, EGFR, and AKT1, were screened according to PPI and molecularly docked with Luteolinidin, and it was found that their binding played a key role in the treatment of tumors. Meanwhile, its active ingredient Luteolinidin was found to induce ROS proliferation to promote apoptosis and prevent cells from entering S phase.

These findings not only explored the anti-gastrointestinal cancer chemical properties of A. absinthium, but also provided a new research direction for the active ingredients and mechanism of action of traditional Chinese medicine.

## Linked entities

- **Genes:** SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714], EGFR (epidermal growth factor receptor) [NCBI Gene 1956], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207]
- **Chemicals:** Luteolinidin (PubChem CID 441701)

## Full-text entities

- **Genes:** EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}
- **Diseases:** tumors (MESH:D009369), gastric and colorectal cancers (MESH:D015179), GIC (MESH:D005770)
- **Chemicals:** Luteolinidin (MESH:C518537), A. absinthium ethanol extract (-)
- **Species:** Artemisia absinthium (species) [taxon 72332]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12597748/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12597748/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12597748/full.md

---
Source: https://tomesphere.com/paper/PMC12597748